Advertisement

Corrigendum Free access | 10.1172/JCI125184

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer

Daniel Nava Rodrigues, Pasquale Rescigno, David Liu, Wei Yuan, Suzanne Carreira, Maryou B. Lambros, George Seed, Joaquin Mateo, Ruth Riisnaes, Stephanie Mullane, Claire Margolis, Diana Miao, Susana Miranda, David Dolling, Matthew Clarke, Claudia Bertan, Mateus Crespo, Gunther Boysen, Ana Ferreira, Adam Sharp, Ines Figueiredo, Daniel Keliher, Saud Aldubayan, Kelly P. Burke, Semini Sumanasuriya, Mariane Sousa Fontes, Diletta Bianchini, Zafeiris Zafeiriou, Larissa Sena Teixeira Mendes, Kent Mouw, Michael T. Schweizer, Colin C. Pritchard, Stephen Salipante, Mary-Ellen Taplin, Himisha Beltran, Mark A. Rubin, Marcin Cieslik, Dan Robinson, Elizabeth Heath, Nikolaus Schultz, Joshua Armenia, Wassim Abida, Howard Scher, Christopher Lord, Alan D’Andrea, Charles L. Sawyers, Arul M. Chinnaiyan, Andrea Alimonti, Peter S. Nelson, Charles G. Drake, Eliezer M. Van Allen, and Johann S. de Bono

Find articles by Rodrigues, D. in: PubMed | Google Scholar

Find articles by Rescigno, P. in: PubMed | Google Scholar

Find articles by Liu, D. in: PubMed | Google Scholar

Find articles by Yuan, W. in: PubMed | Google Scholar

Find articles by Carreira, S. in: PubMed | Google Scholar

Find articles by Lambros, M. in: PubMed | Google Scholar

Find articles by Seed, G. in: PubMed | Google Scholar

Find articles by Mateo, J. in: PubMed | Google Scholar

Find articles by Riisnaes, R. in: PubMed | Google Scholar

Find articles by Mullane, S. in: PubMed | Google Scholar

Find articles by Margolis, C. in: PubMed | Google Scholar

Find articles by Miao, D. in: PubMed | Google Scholar

Find articles by Miranda, S. in: PubMed | Google Scholar

Find articles by Dolling, D. in: PubMed | Google Scholar

Find articles by Clarke, M. in: PubMed | Google Scholar

Find articles by Bertan, C. in: PubMed | Google Scholar

Find articles by Crespo, M. in: PubMed | Google Scholar

Find articles by Boysen, G. in: PubMed | Google Scholar

Find articles by Ferreira, A. in: PubMed | Google Scholar

Find articles by Sharp, A. in: PubMed | Google Scholar

Find articles by Figueiredo, I. in: PubMed | Google Scholar

Find articles by Keliher, D. in: PubMed | Google Scholar

Find articles by Aldubayan, S. in: PubMed | Google Scholar

Find articles by Burke, K. in: PubMed | Google Scholar

Find articles by Sumanasuriya, S. in: PubMed | Google Scholar

Find articles by Fontes, M. in: PubMed | Google Scholar

Find articles by Bianchini, D. in: PubMed | Google Scholar

Find articles by Zafeiriou, Z. in: PubMed | Google Scholar

Find articles by Mendes, L. in: PubMed | Google Scholar

Find articles by Mouw, K. in: PubMed | Google Scholar

Find articles by Schweizer, M. in: PubMed | Google Scholar

Find articles by Pritchard, C. in: PubMed | Google Scholar

Find articles by Salipante, S. in: PubMed | Google Scholar

Find articles by Taplin, M. in: PubMed | Google Scholar

Find articles by Beltran, H. in: PubMed | Google Scholar

Find articles by Rubin, M. in: PubMed | Google Scholar

Find articles by Cieslik, M. in: PubMed | Google Scholar

Find articles by Robinson, D. in: PubMed | Google Scholar

Find articles by Heath, E. in: PubMed | Google Scholar

Find articles by Schultz, N. in: PubMed | Google Scholar

Find articles by Armenia, J. in: PubMed | Google Scholar

Find articles by Abida, W. in: PubMed | Google Scholar

Find articles by Scher, H. in: PubMed | Google Scholar

Find articles by Lord, C. in: PubMed | Google Scholar

Find articles by D’Andrea, A. in: PubMed | Google Scholar

Find articles by Sawyers, C. in: PubMed | Google Scholar

Find articles by Chinnaiyan, A. in: PubMed | Google Scholar

Find articles by Alimonti, A. in: PubMed | Google Scholar

Find articles by Nelson, P. in: PubMed | Google Scholar

Find articles by Drake, C. in: PubMed | Google Scholar

Find articles by Van Allen, E. in: PubMed | Google Scholar

Find articles by de Bono, J. in: PubMed | Google Scholar

Published November 1, 2018 - More info

Published in Volume 128, Issue 11 on November 1, 2018
J Clin Invest. 2018;128(11):5185–5185. https://doi.org/10.1172/JCI125184.
Copyright © 2018, American Society for Clinical Investigation
Published November 1, 2018 - Version history
View PDF

Related article:

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
Daniel Nava Rodrigues, … , Eliezer M. Van Allen, Johann S. de Bono
Daniel Nava Rodrigues, … , Eliezer M. Van Allen, Johann S. de Bono
Clinical Research and Public Health Genetics Oncology

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer

Abstract

BACKGROUND. Understanding the integrated immunogenomic landscape of advanced prostate cancer (APC) could impact stratified treatment selection. METHODS. Defective mismatch repair (dMMR) status was determined by either loss of mismatch repair protein expression on IHC or microsatellite instability (MSI) by PCR in 127 APC biopsies from 124 patients (Royal Marsden [RMH] cohort); MSI by targeted panel next-generation sequencing (MSINGS) was then evaluated in the same cohort and in 254 APC samples from the Stand Up To Cancer/Prostate Cancer Foundation (SU2C/PCF). Whole exome sequencing (WES) data from this latter cohort were analyzed for pathogenic MMR gene variants, mutational load, and mutational signatures. Transcriptomic data, available for 168 samples, was also performed. RESULTS. Overall, 8.1% of patients in the RMH cohort had some evidence of dMMR, which associated with decreased overall survival. Higher MSINGS scores associated with dMMR, and these APCs were enriched for higher T cell infiltration and PD-L1 protein expression. Exome MSINGS scores strongly correlated with targeted panel MSINGS scores (r = 0.73, P < 0.0001), and higher MSINGS scores associated with dMMR mutational signatures in APC exomes. dMMR mutational signatures also associated with MMR gene mutations and increased immune cell, immune checkpoint, and T cell–associated transcripts. APC with dMMR mutational signatures overexpressed a variety of immune transcripts, including CD200R1, BTLA, PD-L1, PD-L2, ADORA2A, PIK3CG, and TIGIT. CONCLUSION. These data could impact immune target selection, combination therapeutic strategy selection, and selection of predictive biomarkers for immunotherapy in APC. FUNDING. We acknowledge funding support from Movember, Prostate Cancer UK, The Prostate Cancer Foundation, SU2C, and Cancer Research UK.

Authors

Daniel Nava Rodrigues, Pasquale Rescigno, David Liu, Wei Yuan, Suzanne Carreira, Maryou B. Lambros, George Seed, Joaquin Mateo, Ruth Riisnaes, Stephanie Mullane, Claire Margolis, Diana Miao, Susana Miranda, David Dolling, Matthew Clarke, Claudia Bertan, Mateus Crespo, Gunther Boysen, Ana Ferreira, Adam Sharp, Ines Figueiredo, Daniel Keliher, Saud Aldubayan, Kelly P. Burke, Semini Sumanasuriya, Mariane Sousa Fontes, Diletta Bianchini, Zafeiris Zafeiriou, Larissa Sena Teixeira Mendes, Kent Mouw, Michael T. Schweizer, Colin C. Pritchard, Stephen Salipante, Mary-Ellen Taplin, Himisha Beltran, Mark A. Rubin, Marcin Cieslik, Dan Robinson, Elizabeth Heath, Nikolaus Schultz, Joshua Armenia, Wassim Abida, Howard Scher, Christopher Lord, Alan D’Andrea, Charles L. Sawyers, Arul M. Chinnaiyan, Andrea Alimonti, Peter S. Nelson, Charles G. Drake, Eliezer M. Van Allen, Johann S. de Bono

×

Original citation: J Clin Invest. 2018;128(10):4441–4453. https://doi.org/10.1172/JCI121924

Citation for this corrigendum: J Clin Invest. 2018;128(11):5185. https://doi.org/10.1172/JCI125184

Charles L. Sawyers’s conflict-of-interest statement was not included in the manuscript. The correct statement is below.

CLS reports coinventorship on patents on enzalutamide (US 7,709,517B2; US 8,183,274B2), licensed to Pfizer, and apalutamide (US 8,445,507; US 9,388,159), licensed to Johnson & Johnson. CLS serves on the board of directors of Novartis, is a cofounder of ORIC Pharmaceuticals, and is a science advisor to Agios, BeiGene, Blueprint Medicines, Column Group, Foghorn Therapeutics, Housey Pharmaceutical Research Laboratories, Nextech, KSQ Therapeutics, Petra Pharma Corp., and PMV Pharma. CLS was a cofounder of Seragon Pharmaceuticals, purchased by Genentech/Roche in 2014.

The authors regret the error.

Footnotes

See the related article at Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

Version history
  • Version 1 (November 1, 2018): Print issue publication
Advertisement
Advertisement